Now if you had reoccurring revenue from OHM it wouldn't matter at all, SP would be at $2 if OHM was successful with the LIFX acquisition. That's the SP difference due to the OHM failure, that's how much OHM is still affecting this company.
Need that reoccurring revenue from OHM going and watch it fly, OHM is the key not LIFX, all IMO.
- Forums
- ASX - By Stock
- BUD
- Ann: Umps Health First Commercial Licensee of LIFX Technology
Ann: Umps Health First Commercial Licensee of LIFX Technology, page-40
Featured News
Add BUD (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online